Autoantibodies Against Glomerular Mesangial Cells and Their Target Antigens in Lupus Nephritis

Figures & data

Table 1. The prevalences of autoantibodies against mesangial cells and their target antigens in Western blot analysis

Bands (kD)	63	52	18	101	74	69	46	36	79	91	24	96
Positive sera from patients with LN (n = 96)	52 (54.2%)	47 (49.0%)	40 (41.7%)	33 (34.4%)	29 (30.2%)	28 (29.2%)	28 (29.2%)	25 (26.0%)	24 (25.0%)	20 (20.8%)	17 (17.7%)	14 (14.6%)
Positive sera from patients with IgAN (n = 25)	1 (4.0%)	3 (12.0%)	0 (0%)	2 (8.0%)	1 (4.0%)	1 (4.0%)	0 (0%)	0 (0%)	1 (4.0%)	0 (0%)	0 (0%)	9 (36.0%)

LN: lupus nephritis.

Figure 1 Western blot analysis of autoantibodies against mesangial cell in sera of patients with lupus nephritis (1). Lane 1: blank control; Lane 2: normal control; Lanes 3 and 4: sera from two patients with lupus nephritis recognized a 101 kD band; Lanes 5 and 9: sera from two patients with lupus nephritis recognized a 91 kD band; Lanes 6 and 7: sera from two patients with lupus nephritis recognized a 69 kD band; Lane 8: sera from a patients with lupus nephritis recognized 96 and 79 kD bands.

Figure 2 Western blot analysis of autoantibodies against mesangial cell in sera of patients with lupus nephritis (2). Lane 1: blank control; Lane 2: normal control; Lanes 3 to 5: sera from three patients with lupus nephritis recognized a 74 kD band; Lane 6: sera from a patients with lupus nephritis recognized 63 and 24 kD bands; Lane 7: sera from a patients with lupus nephritis recognized a 63 kD band; Lane 8: sera from a patients with lupus nephritis recognized 63, 52 and 46 kD bands; Lane 9: sera from a patients with lupus nephritis recognized 63, 52 and 36 kD bands; Lane 10: sera from a patients with lupus nephritis recognized 63, 36, 24 and 18 kD bands; Lane 11: sera from a patients with lupus nephritis recognized a 63 kD band; Lane 12: sera from a patients with lupus nephritis recognized 52, 24 and 18 kD bands; Lane 13: sera from a patients with lupus nephritis recognized 36 and 18 kD band.

Table 2. Associations between autoantibodies against mesangial cell and the pathological type of lupus nephritis

Pathological type	Target antigen (kD)
	63	52	18	101	74	69	46	36	79	91	24	96
Class I (minimal mesangial lupus nephritis) (n = 0)	0	0	0	0	0	0	0	0	0	0	0	0
Class II (mesangial proliferative lupus nephritis) (n = 21)	12	10	7	11	7	7	9	6	4	7	7	4
Class III (focal lupus nephritis) (n = 7)	4	6	5	2	3	4	4	3	2	0	2	0
Class IV (Diffuse lupus nephritis) (n = 49)	26	23	20	14	14	14	12	11	10	9	5	6
Class V (Membranous lupus nephritis) (n = 18)	9	8	8	5	5	3	3	5	8	4	3	4
Class VI (Advanced sclerosis lupus nephritis) (n = 1)	1	0	0	1	0	0	0	0	0	0	0	0
Total	52	47	40	33	29	28	28	25	24	20	17	14

Table 3. Associations between autoantibodis against mesangial cell and the clinicopathological parameters in lupus nephritis

Parameter	No. of patients	No. of positive parameter	Target antigens
			101 kD n = 33	96 kD n = 14	91 kD n = 20	79 kD n = 24	74 kD n = 29	69 kD n = 28	63 kD n = 52	52 kD n = 47	46 kD n = 28	36 kD n = 25	24 kD n = 17	18 kD n = 40
Female	96	82	29 87.9%	12 85.7%	19 95.0%	23 95.8%	25 86.2%	26 92.9%	49 94.2%**	42 89.4%	25 89.3%	25 100%	15 88.2%	34 85.0%
Hematuria	96	76	29 87.9%	12 85.7%	16 80.0%	20 83.3%	28 96.6%**	28 100%	44 84.6%	39 83.0%	26 92.9%	24 96.0%	13 76.5%	2972.5%
Proteinuria ≥ 3.5 g/d	96	56	18 54.5%	9 64.3%	8 40.0%	15 62.5%	18 54.5%	18 62.1%	13 46.5%	29 55.8%	23 48.9%	15 53.6%	13 52.0%	10 58.8%
CCr < 70 mL/min	96	37	11 33.3%	4 28.6%	5 25.0%	6 25%	10 34.5%	8 28.6%	21 40.4%	18 38.3%	11 39.3%	10 40.0%	4 23.5%	16 40.0%
Low C3	96	71	19 57.6%	7 50%	15 75.0%	17 70.8%	22 75.9%	23 82.1%	35 67.3%	35 74.5%	20 71.4%	17 68.0%	14 82.3%	33 82.5%
ANA ( + )	92	68	24 72.7%	11 78.6%	15 75.0%	17 70.8%	23 79.3%	23 82.1%	46 88.5%**	36 76.6%	22 78.6%	21 84.0%	14 82.3%	34 85.0%
Anti-ds-DNA ( + )	90	26	5 15.2%	2 14.3%	4 20.0%	5 20.8%	9 31.0%	7 25.0%	16 30.8%	14 29.8%	9 32.1%	7 28.0%	5 29.4%	16 40.0%
Anti-Ro ( + )	90	27	10 31.4%	4 28.6%	10 50.0%	9 37.5%	13 44.8%	14 50%**	20 38.5%	22 46.8%**	15 53.6%	9 36.0%	5 29.4%	12 30.0%
Anti-La ( + )	90	8	3 9.1%	0 0%	3 15.0%	3 12.5%	4 13.8%	4 14.3%	8 15.4%	8 17.0%**	6 21.4%	3 12.0%	1 5.88%	4 10.0%
Mesangial proliferation	96	92	33 100%	13 92.9%	20 100%	23 95.8%	27 93.1%	28 100%	49 94.2%	47 100%	28 100%	23 92.0%	17 100%	38 95.0%
Active renal pathology	96	72	21 63.6%	9 64.3%	15 75.0%	15 62.5%	21 72.4%	23 82.1%	37 71.2%	36 76.6%	23 82.1%	15 60.0%	13 76.5%	30 75.0%
Clinical activity (SLEDAI ≥ 8)	96	91	32 97.0%	14 100%	20 100%	23 95.8%	28 96.6%	28 100%	52 100%	45 95.7%	27 96.4%	25 100%	17 100%	40 100%

^**P < 0.01.

^*P < 0.05.